REFERENCES
- Al-Jarrah A, Taranikanti V, Lakhtakia R, et al. Idiopathic granulomatous mastitis: Diagnostic strategy and therapeutic implications in Omani patients. Sultan Qaboos Univ Med J. 2013;13:241–247.
- Kessler E, Wolloch Y. Granulomatous mastitis: a lesion clinically simulating carcinoma. Am J Clin Pathol. 1972;58:642–646.
- Akcan A, Akyildiz H, Deneme MA, et al. Granulomatous lobular mastitis: a complex diagnostic and therapeutic problem. World J Surg. 2006;30:1403–1409.
- Al-Khaffaf B, Knox F, Bundred NJ. Idiopathic granulomatous mastitis: a 25-year experience. J Am Coll Surg. 2008;206:269–273.
- Stappaerts I, Colpaert C, Verbraecken J, Van Marck E, Vermeire P. Granulomatous mastitis as presenting sign of Wegener's granulomatosis. Acta Clin Belg. 1999;54:207–210.
- Memis A, Bilgen I, Ustun EE, et al. Granulomatous mastitis: imaging findings with histopathologic correlation. Clin Radiol. 2002;57:1001–1006.
- Shang J, Zhao J, Wu X, et al. Interleukin-33 promotes inflammatory cytokine production in chronic airway inflammation. Biochem Cell Biol. 2015;93:359–366.
- Lu B, Yang M, Wang Q. Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy. J Mol Med (Berl). 2016;94:535–543.
- De la Fuente M, MacDonald TT, Hermoso MA. The IL-33/ST2 axis: Role in health and disease. Cytokine Growth Factor Rev. 2015;26:615–623.
- Hayakawa H., Hayakawa M., Kume A., et al. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J. Biol. Chem. 2007;282:26369–26380.
- Lu DP, Zhou XY, Yao LT, et al. Serum soluble ST2 is associated with ER-positive breast cancer. BMC Cancer. 2014;14:198.
- Gillibert-Duplantier J, Duthey B, Sisirak V, et al. Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma ellmotility, associated with metastasis. Oncogene 2012;31:3516–3524.
- Gopalakrishnan Nair C, Hiran KR, Jacob P, et al. Inflammatory diseases of the non-lactating female breasts. Int J Surg. 2015;13:8–11.
- Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39:206–217.
- Abdollahi A, Ali-Bakhshi A, Farahani Z. Concentration study of high sensitive C—reactive protein and some serum trace elements in patients with benign and malignant breast tumor. Int J Hematol Oncol Stem Cell Res. 2015;9:180–184.
- Allin KH, Nordestgaard BG, Flyger H, et al. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res. 2011;13:R55.
- Tibau A, Ennis M, Goodwin PJ. Post-surgical highly sensitive C-reactive protein and prognosis in early-stage breast cancer. Breast Cancer Res Treat. 2013;141:485–493.
- Cornejo-Juárez P, Vilar-Compte D, Pérez-Jiménez C, et al. Idiopathic granulomatous mastitis. Experience at a cancer center. Rev Invest Clin. 2014;66:393–398.
- Chan DS, Bandera EV, Greenwood DC, et al. Circulating C-reactive protein and breast cancer risk-systematic literature review and meta-analysis of prospective cohort studies. Cancer Epidemiol Biomarkers Prev. 2015;24:1439–1449.
- Basu S, Harris H, Larsson A, et al. Is there any role for Serum Cathepsin S and CRP Levels on prognostic information in breast cancer? The Swedish Mammography Cohort. Antioxid Redox Signal. 2015;23:1298–1302.